For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.
Along with this success, significant efforts are now being placed within discovery of drugs that treat a broader range of RAS mutants beyond G12C. The 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit, will shine a spotlight onto pioneering discovery effort targeting the RAS/MAPK pathway, and benchmark the various innovative modalities being harnessed to target RAS mutations beyond G12C, giving you the opportunity to establish and accelerate your drug discovery platform by targeting the RAS/MAPK pathway at every turn.
Conference + Workshop Day - Drug Developer Pricing - Digital Attendance USD 3146.00,
Conference Only - Drug Developer Pricing - Digital Attendance USD 2099.00,
Conference + Workshop Day - Standard Pricing - Digital Attendance USD 3796.00,
Conference Only - Standard Pricing - Digital Attendance USD 2599.00,
Conference + Workshop Day - Academic Pricing - Digital Attendance USD 2796.00,
Conference Only - Academic Pricing - Digital Attendance USD 1899.00
Speakers: Mallika Singh Vice President, Translational Research Revolution Medicine, Jack Sadowsky Principal Investigator of Discovery Chemistry Carmot Therapeutics, Jeffrey Rothman Assistant Professor, Columbia University Medical Center & CSO, Founder Oncogenuity, Iris Valtingojer Group Leader, Oncology Research Sanofi R&D, Hanna Budayeva Principal Scientific Researcher Genentech, Reagan Jarvis Chief Executive Officer Anocca, Andrea Gohlke Senior Biophysics Scientist AstraZeneca, Armon Sharei CEO & Founder SQZ Biotechnologies, Carmine Fedele Principal Scientist II, Oncology-Drug Discovery Novartis Institute of Biomedical Research, Marcel Frenkel Chief Executive Officer Ten63 Therapeutics, Jeff Ecsedy Chief Scientific Officer Ikena Oncology, Thomas Tibbitts Chief Executive Officer Dogodan Therapeutics, Poulikos Poulikakos Associate Professor Icahn School of Medicine at Mount Sinai, Frantz JeanFrancois Team Lead, RAS initiative Frederick National Laboratory for Cancer Research, Michael Eck Professor, Department of Biological Chemistry & Molecular Pharmacology Harvard Medical School, Raghu Kalluri Professor & Chair, Department of Cancer Biology The University of Texas MD Anderson Cancer Center, Siyuan Le Senior Director of Biology GenFleet Therapeutics, Greg Jones Senior Scientist & Team Leader Pfizer, Sreesha Srinivasa Chief Development Officer Oblique Therapeutics, Mark Hallen Chief Technology Officer Ten63 Therapeutics, Helen Mott Associate Professor, University of Cambridge, Erik Knelson Medical Oncologist Dana-Farber Cancer Institute, Trever Bivona, Professor, Hematology & Oncology, UCSF
Date and Time: Starts: Tue, Feb 22, 2022 at 9:00 AM and Ends: Thu, Feb 24, 2022 at 3:30 PM